Follow-up was done according to EAU guidelines. In 27 patients mIR-371 was evaluated preoperatively and correlated with ...
The study investigators concluded that EV+P demonstrated activity in advanced urothelial carcinoma tumors with histologic ...
The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by ...
(UroToday.com) The 2025 European Society for Medical Oncology (ESMO) Annual Congress was host to a radioligand therapeutics proffered paper session. Dr. Karolien Goffin discussed the previously ...
(UroToday.com) The 2025 European Society of Medical Oncology (ESMO) Annual Congress held in Berlin, Germany between October 17 th and 21 st was host to the Poster presentation session. Dr. J. Connor ...
RENALuT is a phase 2, single-arm trial evaluating the efficacy of [177Lu]Lu-PSMA-617 in patients with second- or third-line metastatic clear cell renal cell carcinoma (ccRCC). The study explores a ...
As such, at ESMO 2025, the investigators analyzed patients with or without baseline bone metastases treated with lenvatinib + pembrolizumab versus sunitinib in the CLEAR study with ∼4 years follow-up ...
KLK2 protein is overexpressed in prostate cancer tissue compared to benign prostate tissue and has been associated with stage and grade. It exits in both secreted and membrane-associated forms, with ...
Among 804 androgen receptor pathway inhibitor-experienced mCRPC patients, 459 patients (57.1%) received another androgen receptor pathway inhibitor as their index therapy and 192 (23.9%) received ...
The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Aurelius Omlin discussing optimized use of immunotherapy and targeted ...
(UroToday.com) The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Channing Paller discussing germline and somatic genetic ...
At the ESMO 2025 annual meeting, Dr. Hansen and colleagues presented the first-in-human data of 212 Pb-ADVC001 in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback